Skip to main content


Page 1 of 4

  1. Asymptomatic childhood cancer survivors (CCS) frequently show decreased exercise performance. Poor exercise performance may indicate impaired future cardiovascular health.

    Authors: Takeshi Tsuda, Kimberly Davidow, Gina D’Aloisio and Joanne Quillen
    Citation: Cardio-Oncology 2023 9:42
  2. There is substantial evidence that systemic anticancer therapies and radiotherapy can increase the long-term risk of cardiovascular disease (CVD). Optimal management decisions for cancer patients therefore nee...

    Authors: Johanna Ramroth, Rebecca Shakir, Sarah C. Darby, David J. Cutter and Valerie Kuan
    Citation: Cardio-Oncology 2023 9:41
  3. The aim was to provide evidence about the prevalence, incidence, and risk factors of cardiac electrical abnormalities in childhood acute lymphoblastic leukemia (ALL) survivors.

    Authors: Émilie Bertrand, Maxime Caru, Audrey Harvey, Philippe Dodin, Vincent Jacquemet and Daniel Curnier
    Citation: Cardio-Oncology 2023 9:40
  4. Percutaneous left atrial appendage occlusion (LAAO) has been rapidly evolving since FDA’s approval in 2015 and has become more of a same-day-discharge procedure. Cancer patient with atrial fibrillation/flutter...

    Authors: Yaqi Zhang, Zhuoran Yang, Muhammad U. Almani, Raquel Soon-Shiong and Bolun Liu
    Citation: Cardio-Oncology 2023 9:39
  5. Osimertinib is a third-generation epidermal growth factor receptor (EGFR) inhibitor that is currently the first-line treatment for metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) due to its favorabl...

    Authors: Karishma Patel, Kristie Y. Hsu, Kevin Lou, Krishan Soni, Yoo Jin Lee, Claire K. Mulvey and Alan H. Baik
    Citation: Cardio-Oncology 2023 9:38

    The Correction to this article has been published in Cardio-Oncology 2023 9:43

  6. Millions of cancer survivors are at risk of cardiovascular diseases, a leading cause of morbidity and mortality. Tools to potentially facilitate implementation of cardiology guidelines, consensus recommendatio...

    Authors: Sherry-Ann Brown, Abdulaziz Hamid, Erin Pederson, Allen Hanna BS, Ragasnehith Maddula, Rachel Goodman, Morgan Lamberg, Pedro Caraballo, Peter Noseworthy, Opeoluwa Lukan, Gift Echefu, Generika Berman and Indrajit Choudhuri
    Citation: Cardio-Oncology 2023 9:37
  7. To determine the impact of acute SARS-CoV-2 infection on patient with concomitant active cancer and CVD.

    Authors: Brijesh Patel, Scott A. Chapman, Jake T. Neumann, Aayush Visaria, Oluwabunmi Ogungbe, Sijin Wen, Maryam Khodaverdi, Priyal Makwana, Jasvinder A. Singh and George Sokos
    Citation: Cardio-Oncology 2023 9:36
  8. Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients. Despite proven efficacy of the monoclonal antibodies, cardiov...

    Authors: Abdulrazaq S. Al-Jazairi, Nahlah Bahammam, Dhai Aljuaid, Lama Almutairi, Shroog Alshahrani, Norah Albuhairan, Peter M. B. Cahusac and Ghazwa B. Korayem
    Citation: Cardio-Oncology 2023 9:35
  9. Immune checkpoint inhibitor (ICI) myocarditis is associated with significant mortality risk. Electrocardiogram (ECG) changes in ICI myocarditis have strong prognostic value. However the impact of complete hear...

    Authors: Michael P. O’Shea, Suganya Arunachalam Karikalan, Ali Yusuf, Timothy Barry, Eiad Habib, John O’Shea, Michael Killian, Eman Baqal, Srishti Nayak, Rajeev Masson, Joerg Hermann, Shimoli Shah, Chadi Ayoub and Hicham El Masry
    Citation: Cardio-Oncology 2023 9:34
  10. Men diagnosed with prostate cancer are at risk for competing morbidity and mortality due to cardiometabolic disease given their advanced age at diagnosis, high prevalence of pre-existing risk factors, and rece...

    Authors: Andrew W. Hahn, Whittney Thoman, Efstratios Koutroumpakis, Amer Abdulla, Sumit K. Subudhi, Ana Aparicio, Karen Basen-Enngquist, Christopher J. Logothetis and Susan C. Gilchrist
    Citation: Cardio-Oncology 2023 9:33
  11. Baseline cardiovascular risk factors correction is recommended in all cancer patients undergoing potentially cardiotoxic therapies. Despite available guidelines, real-world data on dyslipidemia prevalence and ...

    Authors: Massimiliano Camilli, Irma Bisceglia, Maria Laura Canale, Fabio Maria Turazza, Leonardo De Luca, Domenico Gabrielli, Michele Massimo Gulizia, Fabrizio Oliva and Furio Colivicchi
    Citation: Cardio-Oncology 2023 9:32
  12. Patients treated for hematologic malignancy often experience reduced exercise capacity and increased fatigue; however whether this reduction is related to cardiac dysfunction or impairment of skeletal muscle o...

    Authors: Justin M. Canada, John McCarty, Jennifer H. Jordan, Cory R. Trankle, Kevin DeCamp, Josh D. West, Mary Ann Reynolds, Rachel Myers, Katey Sweat, Virginia McGhee, Ross Arena, Antonio Abbate and W. Gregory Hundley
    Citation: Cardio-Oncology 2023 9:31
  13. Cancer survival rates have been steadily improving in the adolescent and young adult (AYA) population, but survivors are at increased risk for cardiovascular disease (CVD). The cardiotoxic effects of anthracyc...

    Authors: Jeannette R. Wong-Siegel, Robert J. Hayashi, Randi Foraker and Joshua D. Mitchell
    Citation: Cardio-Oncology 2023 9:30
  14. Carcinoid syndrome (CS) is a unique constellation of symptoms caused by release of vasoactive substances from neuroendocrine tumors (Pandit et al., StatPearls, 2022). Neuroendocrine tumors are rare with an ann...

    Authors: Aditi Sharma, Maria E. Fierro, Stella Pak, Keerthi Thallapureddy, Moyosore Awobajo, Dawn Hui and Prince Otchere
    Citation: Cardio-Oncology 2023 9:28
  15. 25% of all breast cancer patients have HER-2 overexpression. Breast Cancer patients with HER-2 overexpression are typically treated with HER-2 inhibitors such as Trastuzumab. Trastuzumab is known to cause a de...

    Authors: Prince Otchere, Olusola Adekoya, Samuel B. Governor, Naveen Vuppuluri, Akruti Prabhakar, Stella Pak, Oduro Oppong-Nkrumah, Francis Cook, Rudy Bohinc and Gregory Aune
    Citation: Cardio-Oncology 2023 9:26
  16. Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction.

    Authors: Matthew Dean, Min Jung Kim, Sharon Dimauro, Susan Tannenbaum, Garth Graham, Bruce T. Liang and Agnes S. Kim
    Citation: Cardio-Oncology 2023 9:23
  17. Many ca. survivors exhibit signs of IR, an important risk factor for the development of CAD. CAC scans offer a risk assessment of CV disease before cardiac damage has occurred. We investigated how IR affects C...

    Authors: N. Jacobi, S. Ortman, L. Buda and Daniel Duprez
    Citation: Cardio-Oncology 2023 9:21
  18. Despite the cardiotoxic effect of anthracycline on the left ventricle (LV) was totally identified. The assessment of the anthracycline effect on the right ventricle(RV) by conventional echocardiography was a c...

    Authors: Wafaa S. El-Sherbeny, Nesreen M. Sabry, Shaimaa B. El-Saied and Basma Elnagar
    Citation: Cardio-Oncology 2023 9:20
  19. Though the incidence of atrial fibrillation (AF) is increased in patients with cancer, the effectiveness of catheter ablation (CA) for AF in patients with cancer is not well studied.

    Authors: Sarju Ganatra, Sonu Abraham, Ashish Kumar, Rohan Parikh, Rushin Patel, Sumanth Khadke, Amudha Kumar, Victor Liu, Andrea Nathalie Rosas Diaz, Tomas G. Neilan, David Martin, Bruce Hook, Sourbha S. Dani, Aarti Asnani and Anju Nohria
    Citation: Cardio-Oncology 2023 9:19
  20. Chimeric antigen receptor T- Cell (CAR-T) immunotherapy has been a breakthrough treatment for various hematological malignancies. However, cardiotoxicities such as new-onset heart failure, arrhythmia, acute co...

    Authors: Dae Hyun Lee, Sanjay Chandrasekhar, Michael D. Jain, Rahul Mhaskar, Kayla Reid, Sae Bom Lee, Salvatore Corallo, Melanie J. Hidalgo-Vargas, Abhishek Kumar, Julio Chavez, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina Bachmeier, Rawan Faramand…
    Citation: Cardio-Oncology 2023 9:18
  21. Despite advances in chemotherapy, the drugs used in cancer treatment remain rather harmful to the cardiovascular system, causing structural and functional cardiotoxic changes. Positron-emission tomography asso...

    Authors: Mônica M. C. Becker, Gustavo F. A. Arruda, Diego R. F. Berenguer, Roberto O. Buril, Daniela Cardinale and Simone C. S. Brandão
    Citation: Cardio-Oncology 2023 9:17
  22. Immune checkpoint inhibitors (ICIs) are currently widely used for treatment of various types of cancers. ICI-induced myocarditis, though uncommon, accounts for high risk of major adverse cardiac events and mor...

    Authors: Khan O. Mohammad, Hanna Fanous, Sneha Vakamudi and Yan Liu
    Citation: Cardio-Oncology 2023 9:15
  23. Immune checkpoint inhibitor (ICI) myocarditis is associated with high morbidity and mortality. While endomyocardial biopsy (EMB) is considered a gold standard for diagnosis, the sensitivity of EMB is not well ...

    Authors: Jesus Jimenez, Nicolas Kostelecky, Joshua D. Mitchell, Kathleen W. Zhang, Chieh-Yu Lin, Daniel J. Lenihan and Kory J. Lavine
    Citation: Cardio-Oncology 2023 9:14
  24. Echocardiograms are recommended every 3 months in patients receiving human epidermal growth factor 2 (HER2)-targeted therapy for surveillance of left ventricular ejection fraction (LVEF). Efforts to tailor tre...

    Authors: Anthony F. Yu, Chau T. Dang, Justine Jorgensen, Chaya S. Moskowitz, Patricia DeFusco, Eric Oligino, Kevin C. Oeffinger, Jennifer E. Liu and Richard M. Steingart
    Citation: Cardio-Oncology 2023 9:13
  25. This study aimed to evaluate the association between preoperative hs-cTnI and long-term mortality and major adverse cardiovascular events (MACE) in colorectal cancer patients.

    Authors: Yitao Zhang, Zicheng Huang, Sutian Hu, Jinhong Si, Shiyao Cheng, Zhichong Chen, Jiaojie Xue, Xue Lou, Huajing Peng, Zequan Li, Mao Ouyang, Xiang Gao and Weijie Zeng
    Citation: Cardio-Oncology 2023 9:12
  26. Arterial occlusive events are an emerging problem in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. Endothelial cell damage is thought to play an important role...

    Authors: Tomohiro Kaneko, Sakiko Miyazaki, Azusa Kurita, Ryoko Morimoto, Shun Tsuchiya, Naoki Watanabe, Tomoiku Takaku, Norio Komatsu and Tohru Minamino
    Citation: Cardio-Oncology 2023 9:11
  27. Cancer patients receiving chemotherapy have an increased risk of cardiovascular complications. This limits the widespread use of lifesaving therapies, often necessitating alternate lower efficacy regimens, or ...

    Authors: Ali Mir, Yasra Badi, Seif Bugazia, Anas Zakarya Nourelden, Ahmed Hashem Fathallah, Khaled Mohamed Ragab, Mohammed Alsillak, Sarah Makram Elsayed, Abdulrahman Ibrahim Hagrass, Sawyer Bawek, Mohamad Kalot and Zachary L. Brumberger
    Citation: Cardio-Oncology 2023 9:10
  28. Prostate cancer has a very high prevalence among elder men, and this could potentially increase as longevity in many parts of the world is increasing. Early stages of prostate cancer can have surgical options,...

    Authors: Aswini Kumar, Aswanth Reddy and Arjun Sekar
    Citation: Cardio-Oncology 2023 9:9
  29. Several cohort studies aimed at demonstrating an increased risk of cancer incidence and mortality in patients with a pre-existing diagnosis of heart failure (HF); however, conflicting results have been reporte...

    Authors: Massimiliano Camilli, Juan Guido Chiabrando, Marco Lombardi, Marco Giuseppe Del Buono, Rocco Antonio Montone, Antonella Lombardo, Filippo Crea and Giorgio Minotti
    Citation: Cardio-Oncology 2023 9:8
  30. The many improvements in cancer therapies have led to an increased number of survivors, which comes with a greater risk of consequent/subsequent cardiovascular disease. Identifying effective management strateg...

    Authors: Sherry-Ann Brown, Brian Y. Chung, Krishna Doshi, Abdulaziz Hamid, Erin Pederson, Ragasnehith Maddula, Allen Hanna, Indrajit Choudhuri, Rodney Sparapani, Mehri Bagheri Mohamadi Pour, Jun Zhang, Anai N. Kothari, Patrick Collier, Pedro Caraballo, Peter Noseworthy and Adelaide Arruda-Olson
    Citation: Cardio-Oncology 2023 9:7
  31. Acute myocardial infarction (AMI) and cancer are diseases with high morbidity and mortality worldwide, bringing a serious economic burden, and they share some risk factors. The purpose of this study was to det...

    Authors: Jianfeng Ye, Luming Zhang, Jun Lyu, Yidan Wang, Shiqi Yuan, Zhifeng Qin, Yu Liu, Tao Huang, Jinwei Tian and Haiyan Yin
    Citation: Cardio-Oncology 2023 9:6
  32. Consensus guidelines recommend periodic screening for coronary artery disease (CAD) in Hodgkin lymphoma (HL) survivors treated with radiation therapy (RT) to the chest. However, the prognostic utility of scree...

    Authors: Sanjay Divakaran, Diana M. Lopez, Sean M. Parks, Jon Hainer, Andrea K. Ng, Ron Blankstein, Marcelo F. Di Carli and Anju Nohria
    Citation: Cardio-Oncology 2023 9:5
  33. Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML). While the HMA decitabine, in its ...

    Authors: Ankur Sheel, Junu Bae, Ashlee Asada, Gregory A. Otterson, Ragavendra R. Baliga and Kristin L. Koenig
    Citation: Cardio-Oncology 2023 9:4
  34. Cardiac hemangiomas are very rare benign cardiac tumors. They can present at any age and clinical presentation varies according to location and size. We encountered an 87-year-old woman with a left atrial hema...

    Authors: Leart Berdica, Erisa Kola, Daniela Nakuci, Edlira Horjeti and Mehdi Alimehmeti
    Citation: Cardio-Oncology 2023 9:3
  35. Cancer survivors with prior chest radiation therapy (CXRT) frequently present with atrial fibrillation, heart failure, and have higher overall long-term mortality. There are no data examining the utility of le...

    Authors: Meer R. Zafar, Ashutosh Sharma, Sunitha Shyam Sunder, Badri Karthikeyan, Makoto Nagahama, Andrew Atia, Ronak Bahuva, Saraswati Pokharel, Vijay Iyer, Sharma Kattel and Umesh C. Sharma
    Citation: Cardio-Oncology 2023 9:2
  36. There is limited data on the impact of cardiac disease on long term outcomes of allogeneic stem cell transplant (alloSCT). Our study aims to describe the incidence of late cardiac events after alloSCT, identif...

    Authors: Christine Auberle, Daniel Lenihan, Feng Gao and Amanda Cashen
    Citation: Cardio-Oncology 2023 9:1
  37. Immune checkpoint inhibitors (ICI) are associated with immune-mediated adverse effects, potentially involving any organ. ICI has also been associated with an increased risk of cardiovascular disease in cancer ...

    Authors: Charlie Wang, Sophia Zoungas, Mabel Yan, Rory Wolfe, Andrew Haydon, Mark Shackleton, Mark Voskoboynik, Maggie Moore, Miles C. Andrews, Stephen J. Nicholls and Victoria Mar
    Citation: Cardio-Oncology 2022 8:23
  38. Paclitaxel-induced cardiac ischemia is a rare but life-threatening complication. Although it may be difficult to distinguish from hypersensitivity or infusion reactions, it should not be overlooked. We herein ...

    Authors: Shota Higami, Yusuke Tanaka, Tomomi Deguchi, Mariko Shiraishi and Yasuhiko Shiki
    Citation: Cardio-Oncology 2022 8:22
  39. The full range of cardiovascular complications related to the use of Immune checkpoint inhibitors (ICI) is not fully understood. We aim to describe the spectrum of cardiovascular adverse events (cvAEs) by pres...

    Authors: Maria Sol Andres, Sivatharshini Ramalingam, Stuart D. Rosen, John Baksi, Rajdeep Khattar, Yulia Kirichenko, Kate Young, Nadia Yousaf, Alicia Okines, Robert Huddart, Kevin Harrington, Andrew J.S. Furness, Samra Turajlic, Lisa Pickering, Sanjay Popat, James Larkin…
    Citation: Cardio-Oncology 2022 8:21
  40. We report the case of a 59-year-old female patient with no previous cardiovascular disease treated for Breast cancer with Capecitabine. Shortly after starting treatment, she developed recurrent angina. An exer...

    Authors: George B. Strobel, Shiva P. Ponamgi, Attila Roka and Ahmed S. A. Aboeata
    Citation: Cardio-Oncology 2022 8:19
  41. Neo(adjuvant) systemic treatment regimens containing anthracyclines such as doxorubicin cause a significant risk of heart failure. These regimens are one of the corner stones of osteosarcoma treatment, and the...

    Authors: Julius C. Heemelaar, Jeroen Janson, Jerry Braun, Frank M. Speetjens, Michiel A. J. van de Sande, Juan D. V. Hugo, Daniela Q. C. M. Barge-Schaapveld, Saskia L. M. A. Beeres, Laurens F. Tops, Hans Gelderblom and M. Louisa Antoni
    Citation: Cardio-Oncology 2022 8:18
  42. Cancer chemotherapy using anthracyclines is associated with cardiotoxicity (CTX), and left ventricular ejection fraction (LVEF) analysis is not sensitive to early cardiotoxic changes. Left ventricular global l...

    Authors: Diogo Pereira Santos Sampaio, João Batista Masson Silva, Daniela do Carmo Rassi, Aguinaldo F. Freitas Jr and Salvador Rassi
    Citation: Cardio-Oncology 2022 8:17

Annual Journal Metrics

  • 2022 Citation Impact
    3.3 - 2-year Impact Factor
    0.977 - SNIP (Source Normalized Impact per Paper)
    0.790 - SJR (SCImago Journal Rank)

    2022 Speed
    10 days submission to first editorial decision for all manuscripts (Median)
    130 days submission to accept (Median)

    2022 Usage 
    534 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here